<DOC>
	<DOCNO>NCT01095874</DOCNO>
	<brief_summary>The purpose study compare outcome high risk myelodysplasia patient age 50 70 year without HLA compatible ( 9 10 identity / 10 ) donor . High risk myelodysplasia include IPSS intermediate 2 high myelodysplasia patient sever thrombocytopenia . Patients register acquire risk factor .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation Evaluation High Risk Myelodysplasia : Observational Non-interventional Study</brief_title>
	<detailed_description />
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>50 70 year For myelodysplasia CMML : patient include least one criterion : 1 . IPSSintermediate 1 poor cytogenetics ( complex , 3 7 abnormality ) ; 2. thrombopenia &lt; 20x10ex9/L : 3 . IPSS intermediate 2 high For CMML : patient include least one criterion : 1 . 2 criterion : hyperleucocytosis &gt; 10x10exp9/L , splenomegaly &gt; 18cm , hemoglobin &lt; 10gr/dl , platelet &lt; 100x10ex9/L 2 . IPSS intermediate 2 high Patient eligible transplantation ( include patient without donor ) severe comorbidity include : Renal failure creatinine clearance &lt; 30ml/min Cirrhosis hepatic failure Respiratory disease vital capacity &lt; 30 % Uncontrolled cardiac failure Uncontrolled neurological disease Poor performance status karnofsky &lt; = 60 %</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>myelodysplasia</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>Survival</keyword>
	<keyword>Transplantation</keyword>
</DOC>